132 related articles for article (PubMed ID: 16610768)
1. HBV-ISS (Dynavax).
Sung JJ; Lik-Yuen H
Curr Opin Mol Ther; 2006 Apr; 8(2):150-5. PubMed ID: 16610768
[TBL] [Abstract][Full Text] [Related]
2. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
Sablan BP; Kim DJ; Barzaga NG; Chow WC; Cho M; Ahn SH; Hwang SG; Lee JH; Namini H; Heyward WL
Vaccine; 2012 Mar; 30(16):2689-96. PubMed ID: 22342916
[TBL] [Abstract][Full Text] [Related]
5. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.
Barry M; Cooper C
Expert Opin Biol Ther; 2007 Nov; 7(11):1731-7. PubMed ID: 17961095
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
Cooper C; Mackie D
Expert Rev Vaccines; 2011 Apr; 10(4):417-27. PubMed ID: 21506639
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
[TBL] [Abstract][Full Text] [Related]
9. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S
Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847
[TBL] [Abstract][Full Text] [Related]
10. Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed.
Prescrire Int; 2008 Dec; 17(98):234-6. PubMed ID: 19422145
[TBL] [Abstract][Full Text] [Related]
11. [Hepatitis B immunization for newborn infants of hepatitis B surface antigen-positive mothers].
Cowan SA; Qureshi KM
Ugeskr Laeger; 2007 Oct; 169(41):3471-4. PubMed ID: 17967274
[No Abstract] [Full Text] [Related]
12. Efficacy of low dose intradermal recombinant hepatitis B vaccine with and without immunomodulation in end stage renal disease patients on maintenance hemodialysis.
Sirsat RA; Shah BV; Nair S; Shetty D; Rodriguest C; Mehta A
J Assoc Physicians India; 1995 Mar; 43(3):191-2. PubMed ID: 11256907
[No Abstract] [Full Text] [Related]
13. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant.
Schillie S; Harris A; Link-Gelles R; Romero J; Ward J; Nelson N
MMWR Morb Mortal Wkly Rep; 2018 Apr; 67(15):455-458. PubMed ID: 29672472
[TBL] [Abstract][Full Text] [Related]
14. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.
Marks KM; Kang M; Umbleja T; Avihingsanon A; Sugandhavesa P; Cox AL; Vigil K; Perazzo H; Price JC; Katsidzira L; Vernon C; Alston-Smith B; Sherman KE;
Clin Infect Dis; 2023 Aug; 77(3):414-418. PubMed ID: 37017075
[TBL] [Abstract][Full Text] [Related]
17. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
18. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
Janssen JM; Heyward WL; Martin JT; Janssen RS
Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
[TBL] [Abstract][Full Text] [Related]
20. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme.
Su FH; Chen JD; Cheng SH; Sung KY; Jeng JJ; Chu FY
J Viral Hepat; 2008 Jan; 15(1):14-9. PubMed ID: 18088240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
